168 related articles for article (PubMed ID: 12814457)
1. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics.
Currie GP; Lee DK; Dempsey OJ; Fowler SJ; Cowan LM; Lipworth BJ
Br J Clin Pharmacol; 2003 Jun; 55(6):609-15. PubMed ID: 12814457
[TBL] [Abstract][Full Text] [Related]
2. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge.
Storms W; Chervinsky P; Ghannam AF; Bird S; Hustad CM; Edelman JM;
Respir Med; 2004 Nov; 98(11):1051-62. PubMed ID: 15526805
[TBL] [Abstract][Full Text] [Related]
4. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.
Ilowite J; Webb R; Friedman B; Kerwin E; Bird SR; Hustad CM; Edelman JM
Ann Allergy Asthma Immunol; 2004 Jun; 92(6):641-8. PubMed ID: 15237766
[TBL] [Abstract][Full Text] [Related]
5. Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype.
Sims EJ; Jackson CM; Lipworth BJ
Br J Clin Pharmacol; 2003 Jul; 56(1):104-11. PubMed ID: 12848782
[TBL] [Abstract][Full Text] [Related]
6. Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability.
Zhang J; Yu C; Noonan G; Reiss TF
Clin Ther; 2002 Apr; 24(4):574-82. PubMed ID: 12017402
[TBL] [Abstract][Full Text] [Related]
7. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
Currie GP; Lee DK; Haggart K; Bates CE; Lipworth BJ
Am J Respir Crit Care Med; 2003 May; 167(9):1232-8. PubMed ID: 12456382
[TBL] [Abstract][Full Text] [Related]
8. Montelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: a pilot study.
Gao JM; Cai F; Peng M; Ma Y; Wang B
Chin Med J (Engl); 2013 Jun; 126(12):2229-34. PubMed ID: 23786930
[TBL] [Abstract][Full Text] [Related]
9. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis.
Castro-Rodriguez JA; Rodrigo GJ
Arch Dis Child; 2010 May; 95(5):365-70. PubMed ID: 19946008
[TBL] [Abstract][Full Text] [Related]
10. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
Reiss TF; Chervinsky P; Dockhorn RJ; Shingo S; Seidenberg B; Edwards TB
Arch Intern Med; 1998 Jun; 158(11):1213-20. PubMed ID: 9625400
[TBL] [Abstract][Full Text] [Related]
11. Montelukast: a review of its therapeutic potential in persistent asthma.
Jarvis B; Markham A
Drugs; 2000 Apr; 59(4):891-928. PubMed ID: 10804041
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity.
Busse WW; Casale TB; Dykewicz MS; Meltzer EO; Bird SR; Hustad CM; Grant E; Zeldin RK; Edelman JM
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):60-8. PubMed ID: 16440534
[TBL] [Abstract][Full Text] [Related]
13. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.
Currie GP; Stenback S; Lipworth BJ
Br J Clin Pharmacol; 2003 Jul; 56(1):11-7. PubMed ID: 12848770
[TBL] [Abstract][Full Text] [Related]
14. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids.
Phipatanakul W; Greene C; Downes SJ; Cronin B; Eller TJ; Schneider LC; Irani AM
Ann Allergy Asthma Immunol; 2003 Jul; 91(1):49-54. PubMed ID: 12877449
[TBL] [Abstract][Full Text] [Related]
15. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients.
Tohda Y; Fujimura M; Taniguchi H; Takagi K; Igarashi T; Yasuhara H; Takahashi K; Nakajima S
Clin Exp Allergy; 2002 Aug; 32(8):1180-6. PubMed ID: 12190656
[TBL] [Abstract][Full Text] [Related]
16. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
Lee DK; Jackson CM; Currie GP; Cockburn WJ; Lipworth BJ
Br J Clin Pharmacol; 2003 Nov; 56(5):494-500. PubMed ID: 14651722
[TBL] [Abstract][Full Text] [Related]
17. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast.
Kraft M; Cairns CB; Ellison MC; Pak J; Irvin C; Wenzel S
Chest; 2006 Dec; 130(6):1726-32. PubMed ID: 17166989
[TBL] [Abstract][Full Text] [Related]
18. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
Leff JA; Busse WW; Pearlman D; Bronsky EA; Kemp J; Hendeles L; Dockhorn R; Kundu S; Zhang J; Seidenberg BC; Reiss TF
N Engl J Med; 1998 Jul; 339(3):147-52. PubMed ID: 9664090
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
Pearlman DS; White MV; Lieberman AK; Pepsin PJ; Kalberg C; Emmett A; Bowers B; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2002 Feb; 88(2):227-35. PubMed ID: 11868930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
